COHERUS BIOSCIENCES I
1.3052
25-November-24 13:33:12
15 minutes delayed
Stocks
+0.2152
+19.74%
Today's range
1.1200 - 1.3399
ISIN
N/A
Source
NASDAQ
-
22 Mar 2022 15:30:24 By Nasdaq GlobeNewswire
-
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
15 Mar 2022 07:00:02 By Nasdaq GlobeNewswire
-
Coherus Management to Present at Upcoming Investor Conferences
04 Mar 2022 15:05:00 By Nasdaq GlobeNewswire
-
04 Mar 2022 07:00:00 By Nasdaq GlobeNewswire
-
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results
17 Feb 2022 15:01:00 By Nasdaq GlobeNewswire
-
Coherus Names Paul Reider Chief Commercial Officer
15 Feb 2022 15:30:00 By Nasdaq GlobeNewswire
-
Coherus BioSciences Announces New Employment Inducement Grants
14 Feb 2022 07:30:00 By Nasdaq GlobeNewswire
-
11 Feb 2022 07:30:00 By Nasdaq GlobeNewswire
-
Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors
07 Feb 2022 07:30:01 By Nasdaq GlobeNewswire
-
10 Jan 2022 06:30:00 By Nasdaq GlobeNewswire
-
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors
07 Jan 2022 07:30:00 By Nasdaq GlobeNewswire
-
Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 Jan 2022 07:32:50 By Nasdaq GlobeNewswire
-
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
20 Dec 2021 06:59:00 By Nasdaq GlobeNewswire
-
Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer
17 Dec 2021 08:09:17 By Nasdaq GlobeNewswire
-
Coherus BioSciences Announces New Employment Inducement Grants
16 Dec 2021 15:30:00 By Nasdaq GlobeNewswire
-
15 Nov 2021 07:30:00 By Nasdaq GlobeNewswire
-
Coherus BioSciences Announces New Employment Inducement Grants
10 Nov 2021 15:15:01 By Nasdaq GlobeNewswire
-
Coherus BioSciences Reports Third Quarter 2021 Results
08 Nov 2021 15:01:00 By Nasdaq GlobeNewswire